Bayer to commercialize TRK inhibitor as Roche creates competition 21-Feb-2019 By Maggie Lynch Bayer exercises its option to obtain exclusive licensing rights for the global development and commercialization of Loxo Oncology’s solid tumor drugs.
Lilly bets $8bn on genomic approach to cancer 07-Jan-2019 By Ben Hargreaves Eli Lilly will acquire Loxo for $8bn to gain access to treatments that target cancers dependent on single gene abnormalities.